R
egenerative medicine, broadly speaking, refers to the use of the body's raw materials of repair-namely, cells, matrix, and/or chemical compounds-to naturally restore appearance or function. This strategy applies equally to both life-threatening diseases such as heart attack and cosmetic and reconstructive indications. In many respects, cells are the most critical and elusive members of the "regenerative triad." Cells, unlike many matrix macromolecules, proteins, and small molecules, cannot be manufactured per se. They must be harvested, purified, and in most cases replicated before clinical use. Furthermore, this process must be performed in a manner such that the therapeutic potential of the cells is not dissipated or removed altogether.
Stem cells have received significant attention as an ideal source of regenerative-capable cells because of their multipotentiality and ability to replicate. Furthermore, stem cells have been used in a limited fashion for decades with great clinical success. For example, stem cells from the bone marrow, peripheral blood, and even umbilical cord blood have been used to treat a variety of diseases. 1, 2 Although stem cell therapies can be used allogeneically, the issue of transplant-related immune responses, however, limits the universal applicability of allogenic cell treatments and stem cell therapies. 3 The innate problems associated with allogenic stem cell transplantation such as host immune responses and implant rejection can be avoided by the use of autologous stem cells. Furthermore, autologous stem cells, such as those derived from bone marrow or adipose tissue, can be used clinically for regenerative cell therapy only if they can be obtained in sufficient quantities. Adipose-derived stem cells can be easily processed from lipoaspirated fat and can provide the physician with a significant quantity of multipotent stem cells for a variety of therapeutic regenerative medicine therapies. fat transplantation and synthetic materials. Common materials such as paraffin, rubber, latex, and silicone were all used starting in the early 1900s as soft-tissue fillers. 4 Today, some of these or their man-made progeny are still in use, such as polymethylmethacrylate microbeads marketed as ArteFill. 5 Recently, more sophisticated biologically compatible fillers have been introduced that are made of hyaluronic acid, such as Hylaform and Restylane. 6 -8 All of these fillers, both synthetic and naturally occurring, have significant limitations that are well known to most surgeons. Although these macromolecules are used currently in the clinic as simple soft-tissue fillers, they can also be used as constructs for tissue regeneration. Biomaterials such as these can act as a scaffold support or matrix for surrounding, infiltrating cells or can be mixed ex vivo with a variety of cell types, such as adipocyte precursors 7 or dermal fibroblasts 9 to produce engineered constructs for volume augmentation. A critical constraint of this paradigm is neovascularization of the construct. New growth of blood vessels from the surrounding tissue may take 5 days to infiltrate and provide adequate nutrition, which could result in graft cell death and tissue necrosis. 10 Neuber was the first to publish findings regarding the use of autologous fat transplantation in 1893. He filled scars with autologous fat and found a reduction of transplant resorption by decreasing graft particle size. 11 Unfortunately, despite over 100 years of clinical use since, little has been developed to improve free fat graft performance, and clinical experience has been lackluster. [12] [13] [14] Specifically, the clinical longevity of the graft is highly variable and the volume of large grafts in particular decreases significantly over time. Histologically, progressive loss of transplanted adipocytes is noted along with a conversion of the graft to fibrous tissue, oftentimes with cyst formation. The presumed mechanism of tissue loss appears to be primarily insufficient vascularity and cell death. However, scientific confirmation of this as the only mechanism involved is limited. Other mechanisms such as mechanical disruption of cells, lipid-induced membrane damage, apoptosis, or perhaps other potential mechanisms are possible but have not been well studied.
Clearly, however, both preclinical and clinical studies show that some of the transplanted graft remains, adding to soft-tissue volume. It is presumed that the portion of the graft adjacent to the native recipient blood supply nourishes the graft and sustains it until vascularization occurs. Presumably, more central areas of the graft, that are not so fortunate, die. This concept has led to decreasing the size of fat grafts with the hope that a smaller graft will mean more fat is adjacent to viable recipient tissue, resulting in improved availability and diffusion of cellular nutrition until neovascularization occurs. 15, 16 This concept has been expanded and formalized in the "lipostructure technique" as described by Coleman in 1997. The lipostructure technique describes the microinjection of autologous lipoaspirated fat. 17, 18 This technique works to preserve the fragile nature of the donor adipose tissue and gently transfers these small fat particles to locations near vascularized structures and associated nutrition. Implementation of this technique has led to improved fat grafting outcomes for many surgeons. By combining stem cell therapy with the lipostructure technique, tissue survivability could potentially be enhanced, because stem cells have been shown to enhance angiogenesis 19, 20 and to minimize inflammatory responses.
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THE BIOLOGICAL BASIS FOR SOFT-TISSUE THERAPY USING ADIPOSE-DERIVED STEM CELLS
Currently, scientific and clinical interest is high regarding the potential of stem cells to treat a broad range of conditions. 24 Many sources of cells have been identified, including bone marrow, fat, muscle, liver, skin, heart, and brain in the adult, 25 in addition to fetal and embryonic sources. 26 Stem cells have two basic properties. First, stem cells have the potential to develop or differentiate into many different cell types in the body, such as osteoblasts, myocytes, and adipocytes. 24 -26 Second, stem cells, as they divide, have the potential to self-renew, making yet more stem cells. Age appears to play an important role in stem cell potential. The number of stem cells able to differentiate and their plasticity to differentiate into any tissue appears to diminish with age. [27] [28] [29] On the surface, this may seem to support the use of "younger" stem cell types such as embryonic and fetal stem cells. Unfortunately, despite the ethical quandaries entangling embryonic stem cell usage, there are also key biological limitations with their use as well. 24 Major hurdles such as cell stability, oncogenicity, and spontaneous teratoma formation, in addition to transplantation issues based on the requirement for allogenic cell use or conversely the need for therapeutic cloning to produce autogenicity, represent profound impediments to clinical use, particularly for non-life-threatening indications. As a result, the future clinical use of these cells is, at best, likely many years away.
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For the foreseeable future, adult stem cells represent the most promising source of cells for plastic surgery. Bone marrow, for example, has been shown to contain a population of stem cells that have regenerative potential. Bone marrow mesenchymal stem cells are able to support the repair and regeneration of bone, cartilage, adipose, heart, and even neuronal tissues. 25, 30 However, the use of bone marrow-derived stem cells is limited by the quantity of cells that can be collected from the patient and associated donor-site pain and morbidity. Also, the cells obtained from the bone marrow need to be cultured and expanded in Good Manufacturing Practice-regulated tissue processing facilities for several weeks to generate enough cells for therapeutic use. This procedure is expensive, heavily regulated, and fundamentally changes the biology of the cells. 31 These limitations and others have stimulated interest in a possible therapeutic role of adiposederived stem cells from processed lipoaspirate for many applications, including their use as soft-tissue fillers for plastic and reconstructive surgery. [32] [33] [34] Historically, most biology textbooks list the primary purpose of adipose tissue as a reservoir of energy in the form of triglycerides and as a storehouse for fat-soluble vitamins. Only recently has this source of calories and vitamins been thought of as a source of several types of regenerative cells as well. 35, 36 Armed with this understanding, many new doors are now opened to a variety of potential therapeutic strategies using adipose tissue.
Developmentally, adipose tissue, like bone marrow, is derived from the embryonic mesenchyme and rapidly expands after birth by proliferation of the adipocyte precursor cells and an increase in cellular size. Also like bone marrow, fibroblast-like cells in adipose tissue contain a population of cells that can differentiate toward a number of lineages not limited to the osteogenic, myogenic, chondrogenic, adipogenic, and neurogenic lineages [37] [38] [39] [40] (Table 1) . 36, 37, 39, [41] [42] [43] [44] [45] [46] Adiposederived stem cells can be obtained from the processing of either liposuctioned or excised fat. Despite its ease of harvest and the volume of tissue obtainable from liposuction, adipose contains 100 to 1000 times more pluripotent cells on a percubic centimeter basis than bone marrow. 39, 47 Theoretically, the abundance of isolated stem and therapeutically active cells from adipose eliminates the requirement of cell expansion in tissue culture facilities as is required with bone marrowderived cells and makes these cells readily available to the clinician, at the bedside. In general, fillers currently on the market have not been successful in supporting an engineered tissue replacement therapy for defect repair or tissue restoration. Identifying the appropriate filler in combination with stem cells could provide an optimized microenvironment in which to create an engineered tissue that can be used as a semipermanent filler material. 9 There are a myriad of reasons to suggest that adipose-derived stem cells are perhaps the ideal source of cells for regenerative-based soft-tissue therapies. First, their multipotentiality, especially their proclivity for adipose differentiation, makes them an alluring cell source. It is relatively simple to achieve a high level of adipose differentiation of adipose-derived stem cells in vitro, and many studies have developed methods to use them in vivo. 33, 48 Second, adipose-derived stem cells seem to have a significant potential for angiogenesis and vasculogenesis, one of the fundamental limitations in the current technique of autologous fat transfer. Third, plastic surgeons have a significant comfort level with the harvest and manipulation of adipose tissue. 49 -53 However, early work suggests that adipose-derived stem cells injected into the soft tissue or into a defect will not alone produce soft-tissue fill (M. Zhu et al., unpublished observations, 2005) . A therapeutic strategy must be used to leverage the unique aspects of the cells. One strategy is to use a tissue-engineering approach, combining cells stimulated with certain chemical compounds and placed into a matrix or scaffold to "manufacture" an implantable neoadipose construct. Several potential scaffolds combined with cells have been investigated for their utility for soft-tissue treatment. In one example, preadipocyte cells, which are similar if not identical to adipose-derived stem cells, were combined with the resorbable material Volume 118, Number 3S • Adipose-Derived Stem Cells as Fillers
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poly(lactide-co-glycolide acid). In this study, although initial results were promising, ultimate analysis at 5 to 12 months showed a complete absence of fat and poly(lactide-co-glycolide acid). 48, 54 Another similar study compared the hyaluronic acid sponge, HYAFF 11, with collagen sponges augmented with adipose precursor cells. They found that HYAFF 11 was superior to collagen in supporting the differentiation and expansion of adipose precursor cells. 53 From these studies and others like them, it is difficult to draw clinically meaningful conclusions. However, it suggests that the tissue-engineering approach may be quite difficult to accomplish successfully until more is known regarding the basic signaling involved in stem cell differentiation, cell/matrix interactions, and understanding of adipose-related morphogen biology.
An ingenious approach was used clinically by Llull, who used autologous fat as a matrix and supplemented the transplant with adipose-derived stem cells. He found that this procedure could provide long-term (Ͼ1 year) soft-tissue volume restoration in a patient with soft-tissue involution on the ulnar aspect of one hand. 55 Notably, this patient had previously failed autologous fat grafting alone, which was performed before this adipose-derived stem cell procedure. This case provided evidence that fat itself can provide the matrix for stem cells. The mechanism driving the clinical result is not known, but this single clinical case suggests new potential mechanisms beyond differentiation and invites new therapeutic strategies by which adipose-derived stem cell therapy may one day be broadly useful.
STEM CELL-SUPPLEMENTED FAT GRAFTS
To study the ability of adipose-derived stem cells to provide clinical soft-tissue support, predictive preclinical models are required. Based on the work of Llull and other unpublished work, we developed an in vivo model for characterizing and optimizing stem cell-based methods for soft-tissue augmentation.
In the rodent, the subdermal scalp space represents a highly vascular and accessible yet demanding subcutaneous space for testing the implantation of soft-tissue constructs. Using this approach, we have found that freshly isolated adipose-derived stem cells, when mixed with minced donor fat, can improve the longevity and volume of the graft. 56 In this preliminary study, we used donor stem cells from the adipose tissue of Rosa mice, which are transgenic for ␤-galactosidase (LacZ) and that can be stained blue during histologic evaluation with the chromogenic substrate X-gal. The stem cells were isolated as a heterogenous cell population from lipectomized fat that was enzymatically digested and pelleted by centrifugation to remove the buoyant fraction according to previously published prodedures. 43 Freshly isolated, not cultured, Rosa adipose-derived stem cells or cultured Rosa adipose-derived stem cells were mixed with 100 l of minced adipose tissue from B6;129 sF1/J mice and injected over the skulls of experimental athymic nude mice. The fat was harvested at 6 months and the quantity and quality of the fat observed, as was the presence of the Rosa-derived cells. We found that, 6 months after transplantation, the fat with freshly isolated stem cells had a weight 2.5 times greater than the fat graft-only group (p ϭ 0.021) (Fig. 1) . Also, a trend was noted (p ϭ 0.06) that cultured adiposederived stem cells were greater in maintaining graft volume than fat only. Qualitatively, hematoxylin and eosin evaluation of the transplanted tissues at 6 months demonstrated that the grafted fat supplemented with fresh stem cells maintained its adipocyte-rich appearance, whereas the grafted tissue without cell supplementation group had a more fibrous tissue appearance (Fig. 2) . ␤-Galactosidase staining of fat with fresh adipose-derived Rosa stem cells shows that the stem cells are retained in the graft for at least 6 months. Furthermore, immunohistochemistry of fat with the fresh adipose-derived Rosa stem cells with von Willebrand factor (factor VIII), an endothelial marker, showed an identifiable vascular support for the entire graft at 6 months. This work, although incomplete, suggests that one potential mechanism by which adipose-derived stem cells may work is the improvement of graft blood supply. This is supported by recent work presented by Pinkernell et al., Strem et al., and others, who show convincingly that adipose-derived stem cells improve cardiac function after heart attack in pigs, in part by improving myocardial perfusion. 57, 58 Further studies in vivo, including greater mechanistic detail and longer follow-up of the transplanted cellular constructs, is ongoing.
Building on the clinical feasibility of using adipose-derived stem cell-supplemented fat as a defect filler, Yoshimura and colleagues treated 23 patients with either demonstrable soft-tissue defects or breast augmentation using stem cell-supplemented fat transplantation for soft-tissue fill. These data, which have yet to be published but have been presented in both the United States and Japan, suggest that this approach may be feasible Volume 118, Number 3S • Adipose-Derived Stem Cells as Fillers and effective. 59 In this feasibility series, 23 various cases were treated and followed up to 26 months, with evidence of long-term maintenance of volume in patients treated for either subcutaneous soft-tissue fill or breast enhancement (Fig. 3) . Reported complications were limited to one patient who has exhibited some fibrosis at the central area of the chest over the sternum. However, despite these results, a final determination of the success and potential complications of this early series must be predicated on the complete study and its peer-reviewed evaluation.
CONCLUSIONS
Adipose tissue is plentiful and can be easily obtained using current liposuction techniques. Although fat is inconsistent on its own as a defect filler, adipose tissue can provide a source of stem cells that may be able to either enhance fat grafting or provide the basis for other more unique strategies for soft-tissue regeneration or repair. Although the property of differentiation may be an important aspect of stem cell therapeutic potential, other mechanisms such as vasculogenesis, arteriogenesis, angiogenesis, cell preservation, antiapoptosis, anti-inflammation, and others may underlie the potential effectiveness of adipose-derived stem cells as well. Furthermore, as new therapies are developed using adipose-derived stem cells, the procedure of liposuction will assume a broader role as a preferred method of autologous tissue and cell harvest and not just a cosmetic procedure. 
